Aumenta le possibilità di ricevere una risposta da questo datore di lavoro
Il tuo curriculum e una lettera di presentazione personalizzati, che corrispondono esattamente a ciò che sta cercando.
CSL Behring in Australia is seeking a Principal Process Technology Engineer to lead end-to-end development and governance of process requirements for system design and build on capital and BAU projects. The role involves translating inputs into measurable requirements, driving risk assessments, and ensuring compliance with cGMP in FDA-regulated environments.
You will collaborate with design, manufacturing, QA/RA, and operations to close gaps, lead improvements, and support the Broadmeadows
CSL Limited is a company that fosters a work culture emphasising Superior Performance, Innovation, Integrity, Collaboration and Customer Focus with a commitment to support, train and grow its people. As a genuine leader in the biopharmaceutical industry, CSL is a multinational ASX Listed Company that is actively growing its Australian based manufacturing operations to support global growth. CSL develops, manufactures and markets products to treat and prevent serious human medical conditions and is globally one of the largest manufacturers of plasma-derived therapies.
The Principal Process Technology (PT) Engineer is responsible for applying fundamental engineering knowledge for the design and implementation of new process technology as part of our high priority projects. Working on Capital Projects (Tier 1,2 and 3), OPEX projects and BAU activities, the Principal PT Engineer will be part of a project organization and reporting into this project organization.
Own the definition, documentation, and governance of process requirements for system design and build. Leverage inputs—including technology transfer data—to derive clear, testable requirements, and apply them to drive cross-functional assessments (e.g., risk, readiness, and compliance).
CSL Behring is undergoing extensive and positive change as we expand our capability and capacity. In addition to contributing to Australia’s export economy, CSL has invested in substantial new manufacturing facilities at Broadmeadows that will provide Australia with further high skills science and manufacturing employment opportunities and strengthen capabilities to develop and commercialise future new medicines onshore in Australia.